For the pQTL instruments of IL6R, the alleles associated with higher soluble protein levels of the protein have been shown to lead to lower intracellular pathway activation,37 indicating consistency of direction with the therapeutic approach of IL6 inhibitor on COVID-19.3 This evidence concerns the gene IL6 and COVID-19.